Navigation Links
Genmab Initiates Zalutumumab Combination Study in Colorectal Cancer
Date:5/30/2008

tients will present with or eventually develop metastatic, incurable disease.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using cutting-edge antibody technology, Genmab's world class discovery, development and manufacturing teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders. As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit http://www.genmab.com.

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the pub
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Genmab Announces 2007 First Half Year Results
2. Genmab Announces Encouraging Preclinical Data for ofatumumab
3. Genmab Discloses Target and Development Plans for HuMax-Inflam
4. Genmab Announces Asset Exchange Agreement
5. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
6. Genmab A/S - Company Announcement
7. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. Genmab Announces Results for the First Nine Months of 2007
10. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
11. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  With over 60,000 customers across the globe, ISN ... connect 450 hiring organizations with more than 60,000 safe and reliable contractors in over 80 countries. ... ... ... Headquartered in Dallas, TX ...
(Date:7/30/2015)... NY (PRWEB) , ... July 30, 2015 , ... As part of its 2015 growth ... material and technical service business units, Whitehouse Laboratories is pleased to announce ... be adjacent to the Container Center of Excellence and will be strictly dedicated to basic ...
(Date:7/29/2015)... According to a new market research ... Forecasts (2015-2020), , published by Mordor Intelligence, the Global market ... end of 2020, with North America ... of the global market size. The Global market for Stem ... during the period of (2015-2020).      (Logo: http://photos.prnewswire.com/prnh/20150428/740799) ...
(Date:7/29/2015)...  HealthSouth Corporation (NYSE: HLS ), one ... services, offering both facility-based and home-based post-acute services, ... second quarter ended June 30, 2015. ... growth in both segments and an 11.0% increase ... and Chief Executive Officer of HealthSouth. "While reported ...
Breaking Biology Technology:ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25HealthSouth Reports Results for Second Quarter 2015 26HealthSouth Reports Results for Second Quarter 2015 27HealthSouth Reports Results for Second Quarter 2015 28HealthSouth Reports Results for Second Quarter 2015 29HealthSouth Reports Results for Second Quarter 2015 30HealthSouth Reports Results for Second Quarter 2015 31
... Ltd, a cancer therapeutics,company, today announced the completion ... Bio*One Capital and new investor Aravis Venture.,Additional new ... by,Adamant Biomedical Investments AG and Zurcher Kantonalbank (ZKB). ... development efforts of its,two lead compounds, SB939, a ...
... 19 /Xinhua-PRNewswire-FirstCall/ --,Pharmaceutical company Pharmaxis (ASX: PXS; ... approval to market Aridol from the Swiss ... for measuring airway hyperresponsiveness and within,Europe is ... Finland, France, Germany,Greece, Ireland, The Netherlands, Norway, ...
... the launch of the Mattel UCLA NanoPediatrics Program, ... for children, including the opportunities and risks involved. ... dedicated solely to nanomedicine and pediatric patients. ... Because children are not small adults," said Dr. ...
Cached Biology Technology:S*BIO Completes US$26 Million Equity Financing 2S*BIO Completes US$26 Million Equity Financing 3S*BIO Completes US$26 Million Equity Financing 4Pharmaxis Aridol Approved for Sale in Switzerland 2Mattel Children's Hospital UCLA launches program in nanopediatrics 2
(Date:7/21/2015)... Connecticut , July 21, 2015  NXT-ID, ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet, announces that it has filed ... System and Method. This invention ... not only authorizes an account, but also the ...
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. (NASDAQ: ... announced today that it will report financial results for ... July 30, 2015 after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
(Date:7/8/2015)... , N.J. and NEW YORK , July ... Guidepoint today announced BD & Guidepoint ... companies with free access to Guidepoint,s expert network services. ... that are developing cutting-edge technologies to improve healthcare delivery ... Guidepoint research manager, each start-up entrepreneur will be able ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... evidence that a direct interaction between vitamin D and ... multiple sclerosis (MS). The research, published on 6 February ... that vitamin D deficiency during pregnancy and the early ... MS later in life. MS is the most ...
... (NYSE: CSC ) announced today that it ... and Support Services Unrestricted contract by the Department of ... (IDIQ) contract covers a broad range of services, solutions ... BTF business and program units. The contract has a ...
... Feb. 3 SectorWatch.biz announces the availability of a commentary ... Controls, Inc. (OTC Bulletin Board: FOUR), Magal Security Systems Ltd. ... NSSC ), Pointer Telocation (Nasdaq: PNTR ... Systems Inc. (NYSE: CKP ).To view the FiSpace.net ...
Cached Biology News:Genetic study shows direct link between vitamin D and MS susceptibility 'gene' 2Genetic study shows direct link between vitamin D and MS susceptibility 'gene' 3CSC Awarded Department of Defense Biometrics Contract 2SectorWatch.biz Issues Commentary for Investors of Homeland Defense Companies FOUR, MAGS, NSSC, PNTR, BCO, and CKP 2
... European Collection of Cell Cultures (ECACC) has ... industry, academia and government institutes for over ... course designed to introduce candidates to cell ... focuses on more specialist areas such as ...
... for use in the Microsart e.motion are sterile-sealed, ... in a specially designed individual package on a ... band of membrane filter units ensures that they ... the sealed band guarantees uniform dispensing of the ...
...
...
Biology Products: